永勝醫療(01612.HK)第三季度收入3.99億港元 同比大增212.4%
格隆匯10月22日丨永勝醫療(01612.HK)公佈,集團截至2020年9月30日止三個月的總收入達3.99億港元,較2019年同期增加212.4%,並較截至2020年6月30日止三個月增加7.3%;及集團截至2020年9月30日止九個月的總收入達9.01億港元,較2019年同期增加140.8%。
2020年第三季度,新市場和現有市場對集團的呼吸類器械和耗材的需求繼續穩健,為集團的業務進一步注入動力。集團的inspiredTM器械的裝機量進一步增長,進而帶動來自相關耗材銷售的經常性收入上升。2020年第三季度,來自成像一次性產品的收入較2019年同期增長20.1%,主要是由於新產品銷售增加及原材料供應回覆正常所致。儘管骨科支護復康器具的銷售在2020年上半年受到2019冠狀病毒病大流行的負面影響,集團看到第三季度的銷售訂單有所增加,並預計此趨勢將在2020年第四季度持續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.